IBC's Newly Expanded Event, Discovery-2-Diagnostics, to Take Place in Boston Next Week
Posted on: Monday, 18 September 2006, 15:01 CDT
IBC's newly expanded event, Discovery-2-Diagnostics, focusing on maximizing microarrays, biomarkers and molecular diagnostics to scientifically advance new discoveries and novel technologies, will be taking place September 25-27 at the Hynes Convention Center in Boston. It features three of IBC's highly regarded conferences: 13th Annual Chips to Hits(R), 5th Annual Biomarkers, and 5th Annual Molecular Diagnostics. Download Brochure!
This is the largest and most unique event that focuses on the strategies, tool sets, and alternative uses of technologies and standards that will solve your challenges with the use of biomarkers through discovery to the clinic, proactive approaches to diagnostic commercialization and emerging applications and scientific advances for microarrays. During the three day event, the most prominent executives, scientists and developers within pharma, biotech, academia, and government will gather to attend interactive sessions, debates and panel discussions on the emerging challenges and opportunities within the market. The D2D Exhibition offers 100+ exhibiting companies providing a diverse set of products and solutions that will allow your company to facilitate the processes needed to move down the pipeline from discovery to diagnostics.
Keynote Presentations:
Hear the Results from the FDA-Sponsored Microarray Quality Control Study (MAQC) Facilitated by Leming Shi, Ph.D., NCTR/FDA Technologies and the Impact of Personal Genomics George M. Church, Ph.D., Harvard Medical School Functional Proteomics for Biomarker and Target Identification Joshua LaBaer, Ph.D., Harvard Medical School Institute of Proteomics Moving Biomarkers into Diagnostics Werner Kroll, Head of Biomarker Development, Novartis Integrated Diagnostics for Breast Cancer: Yesterday, Today and Tomorrow Jeffrey S. Ross, M.D., Cyrus Strong Merrill Professor and Chair Department of Pathology and Laboratory Medicine, Albany Medical College Clinical Grade Quality Control for Multiplex Assays: Can we Do It? Stephen R. Master, M.D., Ph.D., FCAP, University of Pennsylvania School of Medicine: and Hospital of the University of Pennsylvania Co-Development of Drugs and Diagnostic Devices -- Don't Forget the Diagnostic Steven Gutman, M.D., FDA
Download Brochure!
ATTENTION CALENDAR EDITORS! For more information on attending Discovery-2-Diagnostics in Boston, Massachusetts visit http://www.discovery2diagnostics.com
From: IBC Life Sciences Contact: Kerry Patterson Email: Contact via http://www.marketwire.com/mw/emailprcntct?id=D8EB3C930033A270
SOURCE: IBC Life Sciences
Source: MARKET WIRE
Related Articles
- Orthovita to Present at the Needham & Company, LLC Seventh Annual Biotechnology and Medical Technology Conference
- Targeted Genetics to Present at the Needham & Company Fifth Annual Biotechnology and Medical Technology Conference
- Orthovita to Present at Needham & Company, LLC, Fifth Annual Biotechnology and Medical Technology Conference
- Adeza to Present at Needham & Company's Fifth Annual Biotechnology and Medical Technology Conference; Webcast Scheduled Thursday, June 15 at 3:30 P.M. ET
- Metabasis to Present at Needham & Company Fifth Annual Biotechnology and Medical Technology Conference
- Abiomed to Present at Needham & Company's Fifth Annual Biotechnology and Medical Technology Conference
- North American Scientific to Present at Needham & Company's Fifth Annual Biotechnology and Medical Technology Conference
- Needham & Company's Fifth Annual Biotechnology and Medical Technology Conference in New York on June 14-15; Medical Technology Companies Included for First Time; Record Number of Companies to Present
- Antigenics CEO to Present at Needham & Company Fifth Annual Biotechnology and Medical Technology Conference
- Depomed to Present at Needham & Company, LLC's Fifth Annual Biotechnology and Medical Technology Conference
 |
 |
User Comments (0)
RSS Feeds